| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |